Continuous use of eye drops in patients with neovascular AMD who receive frequent eye injections soothes dry eye more ...

Latanoprostene bunod 0.024% significantly reduced IOP across patient groups and appeared well regarded among physicians and ...

Opus Genetics' eye drop shows promise for age-related vision loss in Phase 3 trial. Company plans FDA filing to expand medication's approved uses.

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.